| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Tomoyuki Hirai CEO | JPX Exchange | JP3991200001 ISIN |
| Japan Country | 403 Employees | - Last Dividend | - Last Split | - IPO Date |
Wakamoto Pharmaceutical Co.,Ltd., headquartered in Tokyo, Japan, has a distinguished presence in the pharmaceutical industry, primarily focusing on the manufacture and sale of ethical and non-prescription drugs within the Japanese market. Originally established in 1929 under the name Society for Nutrition and Raising Children Co., Ltd., the company underwent a name change to Wakamoto Pharmaceutical Co.,Ltd. in July 1943. Since its inception, Wakamoto Pharmaceutical has dedicated itself to developing pharmaceutical products aimed at improving the health and well-being of its customers.
This product line is designed to aid in digestion, intestinal regulation, and nutritional supplementation. As one of the company's flagship offerings, it targets gastrointestinal health through a blend of ingredients formulated to enhance the digestive process.
An innovative solution tailored for those seeking relief from intestinal discomfort, this drug is a testament to Wakamoto's commitment to addressing gastrointestinal issues with scientifically-backed formulations.
These oral tablets are a dietary supplement aimed at restoring the balance of oral flora. In an era where oral health is increasingly recognized as crucial to overall well-being, AVANTBISE stands out as a preventive measure against imbalances in oral bacteria.
Complementing its oral health lineup, Wakamoto has developed a medicated toothpaste designed to effectively clean teeth while also addressing specific dental concerns. This product underscores the company’s holistic approach to health, extending beyond traditional pharmaceuticals.